August 10, 2017
New Publication Confirms Analytic Validity of Castle Biosciences’ DecisionDx-UM Test for Uveal Melanoma in its Clinical Laboratory

July 18, 2017
Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination and Commercial Insurance Positive Coverage Policies

June 5, 2017
Castle Biosciences Presents Three New Clinical Studies at ASCO 2017 Highlighting the Accuracy and Performance of the DecisionDx-Melanoma Gene Expression Profile Test for Cutaneous Melanoma

May 15, 2017
Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions

May 9, 2017
Oxford Finance and Silicon Valley Bank Close $20 Million Credit Facility with Castle Biosciences

May 1, 2017
Castle Biosciences’ DecisionDx-Melanoma Test Accurately Predicts Metastatic Risk in Patients with Head and Neck Melanoma

March 29, 2017
Blue Cross Blue Shield Association Evidence Street Issues Positive Assessment of Castle Biosciences’ Uveal Melanoma Gene Expression Test

March 20, 2017
Castle Biosciences’ DecisionDx-Melanoma Test Shown to be a Significant Predictor of Distant Metastasis in Elderly Patients with Melanoma

January 23, 2017
Study Demonstrates that DecisionDx-Melanoma Test Improves Identification of High Risk Skin Melanoma When Used with AJCC Outcome Prediction Tool

January 17, 2017
Castle Biosciences’ New Laboratory Receives Accreditation from College of American Pathologists